Digestive Diseases and Sciences

, Volume 63, Issue 12, pp 3465–3473 | Cite as

Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones

  • Hyun Jung Kim
  • Tae Uk Kang
  • Heather Swan
  • Min Ji Kang
  • Nayoung Kim
  • Hyeong Sik Ahn
  • Seon Mee ParkEmail author
Original Article


Background and Aim

Cholangiocarcinoma (CCA) often develops after the hepatic resection for hepatolithiasis as well as indwelling it. We studied the incidence and prognosis of subsequent CCA in patients with hepatolithiasis in South Korea.


We identified individuals with diagnosed CCA at the time of or after surgery, during 2002–2016, from the Korean National Health Insurance. The incidences and survival rates of subsequent CCA were analyzed and compared with concomitant CCA. The standardized incidence ratios (SIRs) of CCA in this cohort were evaluated in the standard Korean population. All data were stratified by the presence of intrahepatic or extrahepatic CCA, age and sex.


Of the 7852 patients with hepatectomy for BDS, 433 (5.84%) had concomitant CCA. Over the 12-year follow-up, 107 of 7419 (1.98%) patients were diagnosed with subsequent CCA. Patients with hepatic resection for BDS revealed higher SIRs for subsequent CCA (12.89, 95% CI 10.96–15.15) in cases of both intrahepatic CCA (13.40, 10.55–17.02) and extrahepatic CCA (12.42, 9.98–15.46). The median survival time for subsequent CCA was 0.87 years, while that for concomitant CCA was 2.79 years. Having subsequent CCA (HR 2.71, 95% CI 2.17–3.40) and being male (HR 1.28, 1.05–1.57) were related to a shorter survival time. The CCA site and age at CCA diagnosis were not related to prognoses.


Subsequent CCA developed in 2% of the patients with hepatic resection for benign BDS until 10 years and was associated with poorer prognoses than concomitant CCA. Future studies focused on the long-term surveillance for CCA in such patients are needed.


Cholangiocarcinoma Bile duct stone Hepatic resection Incidence Mortality 


Compliance with ethical standards

Conflict of interest

All authors declare no potential conflicting interests related to this paper.


  1. 1.
    Kim HJ, Kim JS, Joo MK, et al. Hepatolithiasis and intrahepatic cholangiocarcinoma: a review. World J Gastroenterol. 2015;21:13418–13431.CrossRefGoogle Scholar
  2. 2.
    Catena M, Aldrighetti L, Finazzi R, et al. Treatment of non-endemic hepatolithiasis in a Western country. The role of hepatic resection. Ann R Coll Surg Engl. 2006;88:383–389.CrossRefGoogle Scholar
  3. 3.
    Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology. 2003;50:8–12.PubMedGoogle Scholar
  4. 4.
    Tsuyuguchi T, Miyakawa K, Sugiyama H, et al. Ten-year long-term results after non-surgical management of hepatolithiasis, including cases with choledochoenterostomy. J Hepatobiliary Pancreat Sci. 2014;21:795–800.CrossRefGoogle Scholar
  5. 5.
    Suzuki Y, Mori T, Yokoyama M, et al. Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years. J Hepatobiliary Pancreat Sci. 2014;21:617–622.CrossRefGoogle Scholar
  6. 6.
    Li SQ, Liang LJ, Peng BG, et al. Hepaticojejunostomy for hepatolithiasis: a critical appraisal. World J Gastroenterol. 2006;12:4170–4174.CrossRefGoogle Scholar
  7. 7.
    Lee TY, Chen YL, Chang HC, Chan CP, Kuo SJ. Outcomes of hepatectomy for hepatolithiasis. World J Surg. 2007;31:479–482.CrossRefGoogle Scholar
  8. 8.
    Tabrizian P, Jibara G, Shrager B, Schwartz ME, Roayaie S. Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg. 2012;215:622–626.CrossRefGoogle Scholar
  9. 9.
    Park HM, Hur YH, Cho CK, Koh YS, Kim HJ, Park EK. Incidence of underlying biliary neoplasm in patients after major hepatectomy for preoperative benign hepatolithiasis. Ann Hepatobiliary Pancreat Surg. 2016;20:173–179.CrossRefGoogle Scholar
  10. 10.
    Lee CC, Wu CY, Chen GH. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol. 2002;17:1015–1020.CrossRefGoogle Scholar
  11. 11.
    Chen DW, Tung-Ping Poon R, Liu CL, Fan ST, Wong J. Immediate and long-term outcomes of hepatectomy for hepatolithiasis. Surgery. 2004;135:386–393.CrossRefGoogle Scholar
  12. 12.
    Lin CC, Lin PY, Chen YL. Comparison of concomitant and subsequent cholangiocarcinomas associated with hepatolithiasis: clinical implications. World J Gastroenterol. 2013;19:375–380.CrossRefGoogle Scholar
  13. 13.
    Kim HJ, Kim JS, Suh SJ, et al. Cholangiocarcinoma risk as long-term outcome after hepatic resection in the hepatolithiasis patients. World J Surg. 2015;39:1537–1542.CrossRefGoogle Scholar
  14. 14.
    Hong SN, Kim HJ, Kim KH, Han SJ, Ahn IM, Ahn HS. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2017;45:253–263.CrossRefGoogle Scholar
  15. 15.
    Li SQ, Liang LJ, Peng BG, et al. Outcomes of liver resection for intrahepatic stones: a comparative study of unilateral versus bilateral disease. Ann Surg. 2012;255:946–953.CrossRefGoogle Scholar
  16. 16.
    Suzuki Y, Mori T, Abe N, et al. Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined on the basis of Japanese Multicenter study. Hepatol Res. 2012;42:166–170.CrossRefGoogle Scholar
  17. 17.
    Liu ZY, Zhou YM, Shi LH, Yin ZF. Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study. Hepatobiliary Pancreat Dis Int. 2011;10:626–631.CrossRefGoogle Scholar
  18. 18.
    Meng ZW, Han SH, Zhu JH, Zhou LY, Chen YL. Risk Factors for Cholangiocarcinoma after initial hepatectomy for intrahepatic stones. World J Surg. 2017;41:835–843.CrossRefGoogle Scholar
  19. 19.
    Park JS, Jeong S, Lee DH, et al. Risk factors for longterm outcomes after initial treatment in hepatolithiasis. J Korean Med Sci. 2013;28:1627–1631.CrossRefGoogle Scholar
  20. 20.
    Jeong YI, Shin HE, Lee SE, et al. Prevalence of clonorchis sinensis infection among residents along 5 major rivers in the Republic of Korea. Korean J Parasitol. 2016;54:215–219.CrossRefGoogle Scholar
  21. 21.
    Park B, Jung KW, Oh CM, Choi KS, Suh M, Jun JK. Ten-year changes in the hepatitis B prevalence in the birth cohorts in Korea: results from nationally representative cross-sectional surveys. Medicine (Baltimore). 2015;94:e1469.CrossRefGoogle Scholar
  22. 22.
    Shon HS, Choi HY, Kim JR, et al. Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012. Clin Mol Hepatol. 2015;21:249–256.CrossRefGoogle Scholar
  23. 23.
    Lim SH, Kwon JW, Kim N, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol. 2013;13:104.CrossRefGoogle Scholar
  24. 24.
    Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:221–232.CrossRefGoogle Scholar
  25. 25.
    Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221–1228.CrossRefGoogle Scholar
  26. 26.
    Cai H, Kong WT, Chen CB, et al. Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. BMC Cancer. 2015;15:831.CrossRefGoogle Scholar
  27. 27.
    Uenishi T, Hamba H, Takemura S, et al. Outcomes of hepatic resection for hepatolithiasis. Am J Surg. 2009;198:199–202.CrossRefGoogle Scholar
  28. 28.
    Chen MF, Jan YY, Hwang TL, et al. Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma. Dig Dis Sci. 2000;45:312–316.CrossRefGoogle Scholar
  29. 29.
    Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients. Eur J Surg Oncol. 2014;40:567–575.CrossRefGoogle Scholar
  30. 30.
    Fan ST, Wong J. Complications of hepatolithiasis. J Gastroenterol Hepatol. 1992;7:324–327.CrossRefGoogle Scholar
  31. 31.
    Cheon YK, Cho YD, Moon JH, Lee JS, Shim CS. Evaluation of long-term results and recurrent factors after operative and nonoperative treatment for hepatolithiasis. Surgery. 2009;146:843–853.CrossRefGoogle Scholar
  32. 32.
    Nakanuma Y, Terada T, Tanaka Y, Ohta G. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A Pathol Anat Histopathol. 1985;406:45–58.CrossRefGoogle Scholar
  33. 33.
    Li FY, Cheng NS, Mao H, et al. Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis. World J Surg. 2009;33:2155–2160.CrossRefGoogle Scholar
  34. 34.
    Zhou Q, Gong Y, Huang F, et al. Expression levels and significance of nuclear factor-κB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma. Dig Surg. 2013;30:309–316.CrossRefGoogle Scholar
  35. 35.
    Sung R, Lee SH, Ji M, et al. Epithelial-mesenchymal transition-related protein expression in biliary epithelial cells associated with hepatolithiasis. J Gastroenterol Hepatol. 2014;29:395–402.CrossRefGoogle Scholar
  36. 36.
    Tajima Y, Kanematsu T. Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J Hepato Biliary Pancreat Surg. 2005;12:463–466.CrossRefGoogle Scholar
  37. 37.
    Ohta T, Nagakawa T, Ueda N, et al. Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis. Cancer. 1991;68:2217–2223.CrossRefGoogle Scholar
  38. 38.
    Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case–control study. PLoS ONE. 2013;8:e69981.CrossRefGoogle Scholar
  39. 39.
    Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57:69–76.CrossRefGoogle Scholar
  40. 40.
    Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173–184.CrossRefGoogle Scholar
  41. 41.
    Lim MK, Ju YH, Franceschi S, et al. Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg. 2006;75:93–96.CrossRefGoogle Scholar
  42. 42.
    Antwi SO, Mousa OY, Patel T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995–2014. Ann Hepatol. 2018;17:604–614.CrossRefGoogle Scholar
  43. 43.
    Korean Statistical Information Service. Population by Census, 2016. Accessed August 8, 2018.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Preventive MedicineKorea University College of MedicineSeoulKorea
  2. 2.Health Insurance Policy Research InstituteNational Health Insurance ServiceWonjuKorea
  3. 3.School of Sociology and AnthropologyUniversity of OttawaOttawaCanada
  4. 4.Department of Public Health, Graduate SchoolKorea UniversitySeoulKorea
  5. 5.Department of Internal MedicineSeoul National University College of Medicine and Seoul National University Bundang HospitalSeoulKorea
  6. 6.Department of Internal MedicineChungbuk National University College of Medicine and Chungbuk National University HospitalCheongjuKorea

Personalised recommendations